ADMS News and Press, Adamas Pharmaceuticals Inc. From 04/19/21

Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org ) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced ...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Mee...

Today, we revisit small biopharma name Adamas Pharmaceuticals for the first time in a couple of years. The company managed to see sales traction from GOCOVRI in 2020 despite the pandemic, and the drug just got approved for a new indication as well. A full investment analysis follo...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at ...

Disclosing new data from two pivotal, Phase 3 clinical studies, Adamas Pharmaceuticals ([[ADMS]] -5.1%) said that its FDA approved therapy Gocovri (amantadine) to treat dyskinesia in Parkinson’s disease demonstrated an additional 2.9 hours ON time without dyskinesia in PD patients...

-- Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia - -- GOCOVRI is the first and only therapy for the treatment of OFF and/or dyskinesia for ...

Hall of Fame Resort & Entertainment Company (HOFV) +71% after NFT deal.Dolphin Entertainment (DLPN) +66% after NFT deal.Alithya Group (ALYA) +52% on acquisition of R3D ConseilColor Star Technology (CSCW) +41%.Aptose Biosciences (APTO) +39% on Q4 results.Cinedigm C...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of its previously announced underwritten public offering of 12,500,000 share...

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Adamas Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Adamas Pharmaceuticals (ADMS) -7% premarket on pricing public offering of 12.5M common shares at $4.40/share, for gross proceeds of $55M.Underwriters' over-allotment is an additional 1.875M shares.Offering is expected to close on March 1. For further details see: Adamas Pharmaceuti...